North Carolina is currently home to 2622 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT04173273
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2025
Locations: Queen City Gastroenterology and Hepatology (Endoscopy), Charlotte, North Carolina
Conditions: Crohn's Disease
Register for Updates
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Local Institution - 2121, Charlotte, North Carolina
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Register for Updates
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
NCT03554356
Recruiting
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or \<50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: UNC Chapel Hill, Chapel Hill, North Carolina
Conditions: Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
Register for Updates
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
NCT06828731
Recruiting
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.
Gender:
ALL
Ages:
Between 35 years and 60 years
Trial Updated:
02/11/2025
Locations: Charles George VA Medical Center, Asheville, North Carolina
Conditions: Prediabetes
Register for Updates
RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims
NCT06800066
Recruiting
Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
02/11/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Prevention
Register for Updates
Scheduled or As Needed Pain Regimen?
NCT06495632
Recruiting
The aim of this study is to determine feasibility of a randomized controlled trial and estimates of efficacy for pain control of a scheduled pain regimen versus an as needed pain regimen for participants undergoing same day surgery procedures.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/11/2025
Locations: Cape Fear Valley Medical Center, Fayetteville, North Carolina
Conditions: Pain, Postoperative
Register for Updates
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Register for Updates
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923
Recruiting
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/11/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Epilepsy, Temporal Lobe
Register for Updates
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
NCT06361056
Recruiting
This study explores the overall feasibility, impact, and satisfaction of using the "mHealth app" on clinic workflow for Black or African American women diagnosed with breast cancer. The "mHealth app" which can be used as a platform to share clinical trial education and communication, was created and tested in previous steps of this study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: UNC Cancer Center, Chapel Hill, North Carolina
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
CES for the Treatment of GAD in Young Adults
NCT06124014
Recruiting
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
Gender:
ALL
Ages:
Between 18 years and 21 years
Trial Updated:
02/11/2025
Locations: Carolina Center for Neurostimulation, Chapel Hill, North Carolina
Conditions: Generalized Anxiety Disorder
Register for Updates
CCT-102 or Expectant Management in Delayed Pregnancy Loss
NCT06121063
Recruiting
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
02/11/2025
Locations: Eastern Carolina Women's Center, PA, New Bern, North Carolina
Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss
Register for Updates